Synthesis and activity of functionalizable derivatives of the serotonin (5-HT) 5-HT2A receptor (5-HT2AR) antagonist M100907

被引:6
作者
Gilbertson, Scott R. [1 ,2 ]
Chen, Ying-Chu [1 ]
Soto, Claudia A. [2 ]
Yang, Yaxing [1 ]
Rice, Kenner C. [4 ]
Cunningham, Kathryn A. [2 ,3 ]
Anastasio, Noelle C. [2 ,3 ]
机构
[1] Univ Houston, Dept Chem, Houston, TX 77004 USA
[2] Ctr Addict Res, Bethesda, MD USA
[3] Univ Texas Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA
[4] NIDA, Drug Design & Synth Sect, Mol Targets & Medicat Discovery Branch, Bethesda, MD 20892 USA
关键词
Serotonin; M100907; Volinanserin; Bivalent;
D O I
10.1016/j.bmcl.2018.02.058
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The approach of tethering together two known receptor ligands, to be used as molecular probes for the study of G protein-coupled receptor (GPCR) systems, has proven to be a valuable approach. Selective ligands that possess functionality that can be used to link to other ligands, are useful in the development of novel antagonists and agonists. Such molecules can also be attached to reporter molecules, such as fluorophores, for the study of GPCR dimerization and its role in signaling. The highly selective serotonin (5HT) 5-HT2A receptor (5-HT2AR) antagonist M100907 (volinanserin) is of clinical interest in the treatment of neurological and mental health disorders. Here, we synthesized the most active (+)-M100907 enantiomer as well as a series of derivatives that possessed either an alkyne or an azide. The triazole resulting from the dipolar cycloaddition of these groups did not interfere with the ability of the bivalent ligand to act as an antagonist. Thus, we have synthesized a number of compounds which will prove useful in elucidating the role of the 5-HT2AR in the central nervous system. (C) 2018 Published by Elsevier Ltd.
引用
收藏
页码:1381 / 1385
页数:5
相关论文
共 16 条
[1]  
BERG KA, 1994, MOL PHARMACOL, V45, P826
[2]   Synthesis and Structure-Activity Relationships of Tool Compounds Based on WAY163909, a 5-HT2C Receptor Agonist [J].
Chen, Ying-Chu ;
Hartley, Rachel M. ;
Anastasio, Noelle C. ;
Cunningham, Kathryn A. ;
Gilbertson, Scott R. .
ACS CHEMICAL NEUROSCIENCE, 2017, 8 (05) :1004-1010
[3]   Synergism Between a Serotonin 5-HT2A Receptor (5-HT2AR) Antagonist and 5-HT2CR Agonist Suggests New Pharmacotherapeutics for Cocaine Addiction [J].
Cunningham, Kathryn A. ;
Anastasio, Noelle C. ;
Fox, Robert G. ;
Stutz, Sonja J. ;
Bubar, Marcy J. ;
Swinford, Sarah E. ;
Watson, Cheryl S. ;
Gilbertson, Scott R. ;
Rice, Kenner C. ;
Rosenzweig-Lipson, Sharon ;
Moeller, F. Gerard .
ACS CHEMICAL NEUROSCIENCE, 2013, 4 (01) :110-121
[4]  
de Paulis T, 2001, Curr Opin Investig Drugs, V2, P123
[5]   Exploration of Synthetic Approaches and Pharmacological Evaluation of PNU-69176E and Its Stereoisomer as 5-HT2C Receptor Allosteric Modulators [J].
Ding, Chunyong ;
Bremer, Nicole M. ;
Smith, Thressa D. ;
Seitz, Patricia K. ;
Anastasio, Noelle C. ;
Cunningham, Kathryn A. ;
Zhou, Jia .
ACS CHEMICAL NEUROSCIENCE, 2012, 3 (07) :538-545
[6]   Serotonin 2A receptor antagonists for treatment of schizophrenia [J].
Ebdrup, Bjorn H. ;
Rasmussen, Hans ;
Arnt, Jorn ;
Glenthoj, Birte .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (09) :1211-1223
[7]  
Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO
[8]  
2-X
[9]  
Ravard A, 1996, CHIRALITY, V8, P295, DOI 10.1002/(SICI)1520-636X(1996)8:4<295::AID-CHIR1>3.3.CO
[10]  
2-G